Researchers from the NIHR Maudsley BRC are to lead a pioneering new study into a cannabis-based treatment for people living with dementia. Alzheimer’s Research UK has awarded over £250,000 for the landmark phase II clinical trial of Sativex®, a cannabis-based medicine licenced in the UK. The drug has already been found to be safe in people and has been approved for use in the treatment of muscle stiffness and tightness experienced by people with multiple sclerosis. However, Sativex® is not currently licensed in the UK for any other indication, including treatment of the symptoms of dementia.
By
NIHR Maudsley BRC at 21 Feb 2019
Dr Marcella Fok and Dr Chin-Kuo Chang used CRIS to look at the physical health of people diagnosed with a personality disorder.
By
NIHR Maudsley BRC at 13 Feb 2019
Oxytocin, a hormone most often associated with childbirth, is also known for its effects on social-emotional cognition and behaviour. According to new research supported by the NIHR Maudsley BRC, oxytocin also alters blood flow in the hippocampus — a brain region strongly implicated in the onset of psychosis — in those at clinically high risk of psychosis.
By
NIHR Maudsley BRC at 12 Feb 2019
Several of our researchers led an exploration of sensitive issues raised by a production of Florian Zeller’s The Father, at South London Theatre in West Norwood on Wednesday 6 February. The Q&A session was chaired by the BRC’s Engagement and Impact Fellow, Dr Sally Marlow, and featured Rob Stewart, Professor of Psychiatric Epidemiology and Clinical Informatics, who also leads the BRC’s Informatics cluster.
By
NIHR Maudsley BRC at 11 Feb 2019
Professor Robert Stewart discusses work supported by the MRC Mental Health Data Pathfinder awards as well as a survey about people's views on sharing health data for research purposes, from Pathfinder colleagues at the University of Edinburgh.
By
NIHR Maudsley BRC at 7 Feb 2019
